Stocktoria
SkinHealth Systems Inc. SKIN
SkinHealth Systems Inc. (SKIN) earns a Piotroski F-score of 6/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $300.8M at a -3.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 6/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.247 |
| Retained earnings / assets | -1.035 |
| EBIT / assets | -0.042 |
| Equity / liabilities | 0.139 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SKIN | SkinHealth Systems Inc. | 6/9 | -1.89 | — | -10% |
| PRCT | PROCEPT BioRobotics Corp | 3/9 | 2.18 | — | +37.2% |
| ANGO | ANGIODYNAMICS INC | 5/9 | -1.82 | — | +9.5% |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | 7/9 | 8.52 | 35.8 | +12.5% |
| LMAT | LEMAITRE VASCULAR INC | 6/9 | 8.18 | 37.9 | +13.5% |
| KIDS | ORTHOPEDIATRICS CORP | 4/9 | 2.67 | — | +15.4% |
| CERS | CERUS CORP | 4/9 | -13.54 | — | +16.1% |
About SkinHealth Systems Inc.
SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.
FAQ
Is SKIN financially healthy?
SkinHealth Systems Inc.'s Piotroski F-score is 6/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does SKIN pay a dividend?
No, SkinHealth Systems Inc. does not currently pay a dividend.
How profitable is SKIN?
In FY2025, SkinHealth Systems Inc. had a net margin of -3.2% and a return on equity of -15.6%.
What is the analyst price target for SKIN?
The average Wall-Street price target for SkinHealth Systems Inc. is $1.34, about 107.4% above the recent price, from 6 analysts.
Is SKIN a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SkinHealth Systems Inc.: a Piotroski F-score of 6/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.